US FDA approves AbbVie's drug for Parkinson's disease
- Posted on September 25, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
US FDA approves AbbVie's drug for Parkinson's disease
Sept 25 (Reuters) - The US Food and Drug Administration has approved AbbVie's treatment for Parkinson's disease in adults, the health regulator's website showed on Friday. The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill. It will be sold under the brand name Juvmo, according to the FDA's website.
